Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q3 revenue falls to $537.0 million; raises 2025 adjusted EPS outlook

Mixed Impact 4 of 5 earnings Written later

ICU Medical reported third quarter 2025 revenue of $537.0 million, down from $589.1 million a year earlier, after disposing of its IV Solutions business on May 1, 2025. Its GAAP net loss narrowed to $(3.4) million, or $(0.14) per diluted share, from $(33.0) million, and it raised its full-year 2025 adjusted EBITDA and adjusted EPS guidance. Shareholders get higher profit measures alongside lower sales.

Key points

  • Q3 2025 revenue was $537.0 million versus $589.1 million in Q3 2024; Vital Care revenue fell to $78.0 million from $164.5 million.
  • Q3 2025 GAAP net loss was $(3.4) million, or $(0.14) per diluted share, compared with $(33.0) million, or $(1.35), a year earlier.
  • Q3 2025 adjusted diluted EPS was $2.03 versus $1.59; adjusted EBITDA was $105.9 million versus $94.8 million.
  • Fiscal 2025 adjusted EPS guidance was raised to $7.35–$7.65 from $6.85–$7.15, and adjusted EBITDA guidance to $395 million–$405 million from $380 million–$390 million.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECNov 6, 2025, 4:10 PM ET
Accession number0000883984-25-000034

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.